JP2024523707A5 - - Google Patents

Info

Publication number
JP2024523707A5
JP2024523707A5 JP2024500231A JP2024500231A JP2024523707A5 JP 2024523707 A5 JP2024523707 A5 JP 2024523707A5 JP 2024500231 A JP2024500231 A JP 2024500231A JP 2024500231 A JP2024500231 A JP 2024500231A JP 2024523707 A5 JP2024523707 A5 JP 2024523707A5
Authority
JP
Japan
Prior art keywords
expression cassette
seq
sequence
item
polynucleotide sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024500231A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024523707A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/073574 external-priority patent/WO2023283649A1/en
Publication of JP2024523707A publication Critical patent/JP2024523707A/ja
Publication of JP2024523707A5 publication Critical patent/JP2024523707A5/ja
Pending legal-status Critical Current

Links

JP2024500231A 2021-07-08 2022-07-08 遺伝子治療のための最適化された発現カセット Pending JP2024523707A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163219651P 2021-07-08 2021-07-08
US63/219,651 2021-07-08
PCT/US2022/073574 WO2023283649A1 (en) 2021-07-08 2022-07-08 Optimized expression cassettes for gene therapy

Publications (2)

Publication Number Publication Date
JP2024523707A JP2024523707A (ja) 2024-06-28
JP2024523707A5 true JP2024523707A5 (enExample) 2025-07-16

Family

ID=83270905

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024500231A Pending JP2024523707A (ja) 2021-07-08 2022-07-08 遺伝子治療のための最適化された発現カセット

Country Status (12)

Country Link
US (2) US12151001B2 (enExample)
EP (1) EP4367251A1 (enExample)
JP (1) JP2024523707A (enExample)
KR (1) KR20240032971A (enExample)
AR (1) AR126407A1 (enExample)
AU (1) AU2022307365A1 (enExample)
CA (1) CA3224488A1 (enExample)
CO (1) CO2024001148A2 (enExample)
IL (1) IL309742A (enExample)
MX (1) MX2024000175A (enExample)
TW (1) TW202317768A (enExample)
WO (1) WO2023283649A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021142267A1 (en) 2020-01-08 2021-07-15 Scarpmap Llc Methods and computing system for processing ultrasound image to determine health of subdermal tissue
WO2022032226A1 (en) 2020-08-07 2022-02-10 Spacecraft Seven, Llc Plakophilin-2 (pkp2) gene therapy using aav vector
TW202317768A (zh) 2021-07-08 2023-05-01 美商特納亞治療股份有限公司 用於基因療法的優化表現卡匣
CA3240080A1 (en) * 2021-12-08 2023-06-15 Christopher Dean HERZOG Junctophilin-2 (jph2) gene therapy using aav vector
KR20250169529A (ko) * 2023-02-13 2025-12-03 아스트라제네카 아일랜드 리미티드 유전자 요법을 위한 Bcl2-관련 아타노진 3(BAG3)을 인코딩하는 핵산
WO2024215655A1 (en) 2023-04-10 2024-10-17 Tenaya Therapeutics, Inc. Cardioprotective bag3 therapies
EP4695396A1 (en) 2023-04-10 2026-02-18 Tenaya Therapeutics, Inc. Guide rnas, vectors, and virions for targeting mutations in the pln gene
AU2024294136A1 (en) * 2023-07-20 2026-02-05 Children's Medical Research Institute Modified cardiotropic aav capsid polypeptides and vectors
WO2025162449A1 (en) * 2024-01-30 2025-08-07 Inspirar Limited Compositions and methods for the treatment of heart disease
WO2025171086A1 (en) * 2024-02-07 2025-08-14 Asimov Inc. Promoters and uses thereof
WO2026099582A1 (en) * 2024-11-08 2026-05-15 Oxford University Innovation Limited Constructs for rna expression

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
AU4645697A (en) 1996-09-11 1998-04-02 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Aav4 vector and uses thereof
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
JP2002511259A (ja) 1998-04-09 2002-04-16 ジェンセット 5’estおよびコードされるヒトタンパク質
DE69939169D1 (de) 1998-05-28 2008-09-04 Us Gov Health & Human Serv Aav5 vektoren und deren verwendung
US6984517B1 (en) 1998-05-28 2006-01-10 The United States Of America As Represented By The Department Of Health And Human Services AAV5 vector and uses thereof
US6759237B1 (en) 1998-11-05 2004-07-06 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
DE69936104T2 (de) 1998-11-05 2008-01-17 The Trustees Of The University Of Pennsylvania Nukleinsäuresequenzen des adeno-assoziierten virus des serotyps i, und vektoren und wirtszellen, die diese enthalten
US20020077470A1 (en) 1999-04-26 2002-06-20 Walker Michael G. Cardiac muscle-associated genes
FR2797273B1 (fr) * 1999-08-06 2004-01-02 Pasteur Institut Polynucleotides dirigeant l'activation de l'expression d'un gene dans le coeur et ses applications a la therapie genique
AU7061401A (en) * 2000-07-05 2002-01-14 Transgene Sa Chimeric promoters for controlling expression in smooth muscle cells
WO2002053703A2 (en) 2001-01-05 2002-07-11 Children's Hospital, Inc. Aav2 vectors and methods
CN103589692B (zh) 2001-11-13 2018-07-24 宾夕法尼亚大学托管会 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
EP1463805B1 (en) 2001-12-17 2014-10-22 The Trustees of The University of Pennsylvania Adeno-associated virus (aav) serotype 9 sequences, vectors containing same, and uses therefor
DK2359869T3 (en) 2001-12-17 2019-04-15 Univ Pennsylvania Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof
PL2657248T3 (pl) 2003-06-19 2017-09-29 Genzyme Corporation Wiriony AAV o zmniejszonej immunoreaktywności i ich zastosowanie
US9233131B2 (en) 2003-06-30 2016-01-12 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
EP1668143B1 (en) 2003-09-30 2013-03-20 The Trustees of The University of Pennsylvania Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
EP1828390B1 (en) 2004-12-15 2012-06-13 The University Of North Carolina At Chapel Hill Chimeric vectors
US9725485B2 (en) 2012-05-15 2017-08-08 University Of Florida Research Foundation, Inc. AAV vectors with high transduction efficiency and uses thereof for gene therapy
DK2623605T3 (en) 2007-04-09 2019-03-25 Univ Florida RAAV VECTOR COMPOSITIONS WITH TYROSIN MODIFIED CAPSIDE PROTEINS AND PROCEDURES FOR USE THEREOF
US8632764B2 (en) 2008-04-30 2014-01-21 University Of North Carolina At Chapel Hill Directed evolution and in vivo panning of virus vectors
EP2396343B1 (en) 2009-02-11 2017-05-17 The University of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
EP2494058B1 (en) 2009-10-29 2017-04-05 Vib Vzw Cardiac-specific nucleic acid regulatory elements and methods and use thereof
US8927514B2 (en) 2010-04-30 2015-01-06 City Of Hope Recombinant adeno-associated vectors for targeted treatment
DK3693025T3 (da) 2011-04-22 2022-01-10 Univ California Adenoassocierede virus-virioner med variant capsid og fremgangsmåder til anvendelse heraf
US9434928B2 (en) 2011-11-23 2016-09-06 Nationwide Children's Hospital, Inc. Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides
PT2945642T (pt) * 2013-01-17 2024-05-27 Medizinische Hochschule Hannover Proteína do fator 1 para utilização no tratamento ou prevenção de doenças
EP2792742A1 (en) * 2013-04-17 2014-10-22 Universitätsklinikum Hamburg-Eppendorf (UKE) Gene-therapy vectors for treating cardiomyopathy
EP3043866A4 (en) 2013-09-12 2017-05-17 President and Fellows of Harvard College Methods for inducing glucose uptake
WO2015127128A2 (en) 2014-02-19 2015-08-27 University Of Massachusetts Recombinant aavs having useful transcytosis properties
EP3113787B1 (en) 2014-03-04 2019-12-04 University of Florida Research Foundation, Inc. Improved raav vectors and methods for transduction of photoreceptors and rpe cells
US10370432B2 (en) 2014-10-03 2019-08-06 University Of Massachusetts Heterologous targeting peptide grafted AAVS
WO2016065001A1 (en) 2014-10-21 2016-04-28 University Of Massachusetts Recombinant aav variants and uses thereof
AU2016366549B2 (en) 2015-12-11 2022-11-10 California Institute Of Technology Targeting peptides for directing adeno-associated viruses (AAVs)
US11124546B2 (en) 2015-12-14 2021-09-21 The University Of North Carolina At Chapel Hill Modified capsid proteins for enhanced delivery of parvovirus vectors
US10570183B2 (en) * 2016-04-19 2020-02-25 The Board Of Regents Of The University Of Texas System Use of a small native peptide activator of SERCA pump for treatment of heart failure and other disorders characterized by cytosolic calcium overload
WO2017192750A1 (en) 2016-05-04 2017-11-09 Oregon Health & Science University Recombinant adeno-associated viral vectors
JP7100629B2 (ja) 2016-06-09 2022-07-13 セントレ・ナショナル・デ・ラ・レシェルシェ・サイエンティフィーク 化学修飾されたカプシドを有するraav
WO2018026766A1 (en) 2016-08-01 2018-02-08 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods for treating cardiac injury
EP3583220A4 (en) 2017-02-15 2021-07-07 The University of North Carolina at Chapel Hill PROCEDURES AND COMPOSITIONS FOR GENERAL TRANSFER IN THE VASCULAR SYSTEM
CA3052705A1 (en) 2017-02-24 2018-08-30 The Board Of Regents Of The University Of Texas System Compositions and methods relating to myomixer-promoted muscle cell fusion
KR102616820B1 (ko) * 2017-03-17 2023-12-21 애드베룸 바이오테크놀로지스, 인코포레이티드 향상된 유전자 발현을 위한 조성물 및 방법
WO2018222503A1 (en) 2017-05-31 2018-12-06 The Regents Of The University Of California Adeno-associated virus with variant capsid and methods of use thereof
US11512327B2 (en) 2017-08-03 2022-11-29 Voyager Therapeutics, Inc. Compositions and methods for delivery of AAV
GB2571704A (en) * 2018-02-22 2019-09-11 Georg August Univ Gottingen Stiftung Offentlichen Rechts Univer Sitatsmedzin Goettingen Prevention or treatment of cardiac arrhytmia and sudden cardiac death
EP3820537A4 (en) * 2018-07-12 2022-04-13 Spacecraft Seven, LLC GENE THERAPY VECTORS FOR TREATMENT OF DANON DISEASE
KR20210102870A (ko) * 2018-08-30 2021-08-20 테나야 테라퓨틱스, 인코포레이티드 미오카르딘 및 ascl1을 사용한 심장 세포 재프로그래밍
BR112021009913A2 (pt) 2018-12-05 2021-08-17 Abeona Therapeutics, Inc. vetor viral adeno-associado recombinante para inserção gênica
JP2022516515A (ja) * 2018-12-31 2022-02-28 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル Rna標的化crispr-cas13bを使用するdux4 rna発現停止
CN113727992A (zh) 2019-03-21 2021-11-30 斯特里迪比奥公司 重组腺相关病毒载体
JP7659271B2 (ja) 2019-03-28 2025-04-09 ザ ジェネラル ホスピタル コーポレイション 導入遺伝子発現のための操作されたアデノ随伴(aav)ベクター
WO2021142267A1 (en) 2020-01-08 2021-07-15 Scarpmap Llc Methods and computing system for processing ultrasound image to determine health of subdermal tissue
FI4103214T3 (fi) * 2020-02-13 2026-07-03 Tenaya Therapeutics Inc Geeniterapian vektorit sydänsairauden hoitoon
US20230241249A1 (en) 2020-07-07 2023-08-03 The Board Of Regents Of The University Of Texas System Adeno-associated virus vector for dwarf open reading frame
WO2022032226A1 (en) * 2020-08-07 2022-02-10 Spacecraft Seven, Llc Plakophilin-2 (pkp2) gene therapy using aav vector
TW202317768A (zh) 2021-07-08 2023-05-01 美商特納亞治療股份有限公司 用於基因療法的優化表現卡匣

Similar Documents

Publication Publication Date Title
Kieserman et al. Current landscape of heart failure gene therapy
JP2021531752A5 (enExample)
JP2022520232A5 (enExample)
JP2026050416A (ja) ダノン病およびオートファジーの他の障害の治療のための方法
JP2023535956A5 (enExample)
JP2020048571A5 (enExample)
WO2023283649A1 (en) Optimized expression cassettes for gene therapy
US20230133924A1 (en) Optimized expression cassettes for gene therapy
JP2022531809A (ja) ATPase媒介性疾患の処置のための組成物および方法
JP2025512574A5 (enExample)
JP7061067B2 (ja) クリグラー・ナジャー症候群の処置のための組成物
JP2023514242A5 (enExample)
JP2024041821A5 (enExample)
JP7654562B2 (ja) 線維芽細胞増殖因子23関連低リン血症性疾患の遺伝子療法
JP2023537904A5 (enExample)
JP2024546103A5 (enExample)
JP2023503850A5 (enExample)
JP2024545183A5 (enExample)
JP2024545507A5 (enExample)
JP2024545186A5 (enExample)
JP2023539247A (ja) Glp-1受容体アゴニスト融合物をコードするウイルスベクター及びネコの代謝性疾患の治療におけるその使用
US11077208B2 (en) Wilson's disease gene therapy
EP4493226A1 (en) Modified muscle-specific promoters
JP2022525848A5 (enExample)
JP2024514110A5 (enExample)